Zobrazeno 1 - 10
of 29
pro vyhledávání: '"W G, Harker"'
Autor:
Mark G. Kris, J F Kessler, John D. Hainsworth, Eric P. Lester, Thomas M. Beck, D Griffen, Paul J. Hesketh, J R Cohen, M Uhlenhopp, W G Harker
Publikováno v:
Journal of Clinical Oncology. 13:2117-2122
PURPOSE This pilot, open-label study evaluates the antiemetic efficacy and safety of a single 20-mg intravenous (IV) dose of dexamethasone combined with a single IV dose of ondansetron (32, 24, or 8 mg) in patients receiving highly emetogenic (HE), m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e0363d4ae1dca723faefa4655952f37
https://doi.org/10.1200/jco.1995.13.8.2117
https://doi.org/10.1200/jco.1995.13.8.2117
Autor:
Thomas J. Ryan, J A Kish, L J Bricker, W K Murphy, Paul J. Hesketh, Thomas M. Beck, John D. Hainsworth, W. H. Harvey, W G Harker, B Haley
Publikováno v:
Journal of Clinical Oncology. 12:596-600
PURPOSE This study compares the efficacy and safety of ondansetron alone with that of ondansetron plus dexamethasone in the prevention of emesis induced by high-dose cisplatin (> or = 100 mg/m2). PATIENTS AND METHODS This multicenter study used a ran
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e791782951f3278fd8784c24beb373de
https://doi.org/10.1200/jco.1994.12.3.596
https://doi.org/10.1200/jco.1994.12.3.596
Autor:
M Wolfe, D E Crawford, Ronald L. Stephens, Ronald M. Bukowski, W G Harker, Ellen R. Gaynor, H S Levine
Publikováno v:
Journal of Clinical Oncology. 11:161-165
PURPOSE Previous reports of chemotherapy in patients with adrenal cancer have described responses to cisplatin (CDDP). Because of these reports of good results, a phase II trial that used CDDP with and without mitotane (o,p'DDD) was initiated. PATIEN
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::604f18efa38361d0916d12e31c9a2835
https://doi.org/10.1200/jco.1993.11.1.161
https://doi.org/10.1200/jco.1993.11.1.161
Publikováno v:
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 10(3)
Topoisomerase II (Topo II) is the target for several chemotherapeutic agents, including doxorubicin and etoposide, termed Topo II poisons. Previous studies from cancer cell lines and clinical specimens attempted to correlate expression of Topo II wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5163fc18283a7e5168d1ec1c0d689aab
https://pubmed.ncbi.nlm.nih.gov/9071722
https://pubmed.ncbi.nlm.nih.gov/9071722
Publikováno v:
Cancer research. 55(21)
Topoisomerase II alpha is an essential nuclear enzyme involved in DNA replication and a target for many of the clinically useful antineoplastic agents. In a mitoxantrone-selected human leukemia cell line, HL-60/MX2, cellular topoisomerase II (topo II
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b93c93634e45f55599cfdb829e4d23aa
https://pubmed.ncbi.nlm.nih.gov/7585537
https://pubmed.ncbi.nlm.nih.gov/7585537
Publikováno v:
Cancer research. 55(8)
A human HL-60 leukemia cell line selected for resistance to mitoxantrone, HL-60/MX2, displays cross-resistance only to agents whose cytotoxicities result from interaction with the nuclear enzyme DNA topoisomerase II (topo II). The topo II catalytic a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::04bf5fb7900d094537df0cbf280a3165
https://pubmed.ncbi.nlm.nih.gov/7712479
https://pubmed.ncbi.nlm.nih.gov/7712479
Publikováno v:
Cancer research. 55(6)
We developed previously a resistant cell line, CEM/C2, from the human leukemia cell line CCRF-CEM by stepwise selection in camptothecin. This cell line is 974-fold more resistant to camptothecin than parental cells. Resistance is only partially expla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6a5f8c346e732c641da83c976c2fec7f
https://pubmed.ncbi.nlm.nih.gov/7882333
https://pubmed.ncbi.nlm.nih.gov/7882333
Publikováno v:
Oncology research. 7(2)
Two camptothecin-resistant variants of the CEM human leukemia cell line were developed by stepwise selection in camptothecin (CPT) in vitro. The two lines, named CEM/C1 and CEM/C2, were found to be approximately 31- and 970-fold less sensitive to CPT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9aace4eee1d47b641da6818d82c5ba7f
https://pubmed.ncbi.nlm.nih.gov/7579731
https://pubmed.ncbi.nlm.nih.gov/7579731
Autor:
Jane Bromund, H. Zeigler, W. G. Harker, J. T. Beck, S. J. Hager, J. E. Reeves, Denise A. Yardley, R. Borson, D. Drosick, W. L. Horvath, Datchen Fritz Tai
Publikováno v:
Journal of Clinical Oncology. 29:1052-1052
1052 Background: Bevacizumab with chemotherapy has shown improvement in progression-free survival (PFS) in MBC patients (pts) (Miller 2007; Miles 2008; Brufsky 2009; Robert, et al 2009). We examine...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::11faa357bde7bae11d1a802d87b24ddb
https://doi.org/10.1200/jco.2011.29.15_suppl.1052
https://doi.org/10.1200/jco.2011.29.15_suppl.1052
Autor:
M K, Danks, M R, Warmoth, E, Friche, B, Granzen, B Y, Bugg, W G, Harker, L A, Zwelling, B W, Futscher, D P, Suttle, W T, Beck
Publikováno v:
Cancer research. 53(6)
Five cell lines selected for resistance to the cytotoxicity of inhibitors of DNA topoisomerase II have point mutations in the gene that codes for the M(r) 170,000 form of this enzyme. In each case, the mutation results in an amino acid change in or n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::596cd5c3a530e8f29d974e328762e1ae
https://pubmed.ncbi.nlm.nih.gov/8383009
https://pubmed.ncbi.nlm.nih.gov/8383009